Formulation and evaluation of bendamustine loaded polymeric nanoparticle
By: Telsang, Mallikarjun
.
Contributor(s): Pradeep, D.
Publisher: Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022Edition: Vol.56(2), Apr-June.Description: 414-419p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical education and researchSummary: Background: Bendamustine-loaded albumin nanoparticles were prepared using different
concentrations of Bovine Serum Albumin (BSA) with the goal of delivering the medication
to particular cancer cells. Materials and Procedures: The nanoparticles were prepared using
simple coacervation technique with increasing concentrations of BSA. The nanoparticles
were characterized for process yield, particle size, surface morphology, drug loading
capacity (%), particle size distribution (Polydispersity index),
in-vitro drug release. The
drug release kinetics were studies using different dissolution models. The drug loading
capacity of the produced nanoparticles varied from 10.4% to 19%. Formulation (F1) had a
mean particle size of approximately 122.4 nm and polydispersivity index of 0.432 across
the different compositions. Bendamustine nanoparticles exhibit sustained drug release
with almost 51.8% bendamustine released in one day. The drug release kinetics follows
Korsmeyer-Peppas model with a Fickian drug release mechanism. The Bendamustine
nanoparticles were found to be stable for a month at 40±5C and 75±5% relative
humidity. Conclusion: Bendamustine loaded BSA nanoparticles were developed which
were found to exhibit a sustained drug release profile. Albumin based Bendamustine
nanoparticles have the potential to be explored further for the better management of the
cancer chemotherapy with reduced side effects.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2022-1425 |
Background: Bendamustine-loaded albumin nanoparticles were prepared using different
concentrations of Bovine Serum Albumin (BSA) with the goal of delivering the medication
to particular cancer cells. Materials and Procedures: The nanoparticles were prepared using
simple coacervation technique with increasing concentrations of BSA. The nanoparticles
were characterized for process yield, particle size, surface morphology, drug loading
capacity (%), particle size distribution (Polydispersity index),
in-vitro drug release. The
drug release kinetics were studies using different dissolution models. The drug loading
capacity of the produced nanoparticles varied from 10.4% to 19%. Formulation (F1) had a
mean particle size of approximately 122.4 nm and polydispersivity index of 0.432 across
the different compositions. Bendamustine nanoparticles exhibit sustained drug release
with almost 51.8% bendamustine released in one day. The drug release kinetics follows
Korsmeyer-Peppas model with a Fickian drug release mechanism. The Bendamustine
nanoparticles were found to be stable for a month at 40±5C and 75±5% relative
humidity. Conclusion: Bendamustine loaded BSA nanoparticles were developed which
were found to exhibit a sustained drug release profile. Albumin based Bendamustine
nanoparticles have the potential to be explored further for the better management of the
cancer chemotherapy with reduced side effects.
Click on an image to view it in the image viewer
There are no comments for this item.